Abstract
Background Glucose is the main source of energy for the human body. The liver plays an important role in physiological glycemic control as it produces, stores & release glucose depending on our need for glucose through involvement in several glucose metabolism processes including glycogenesis & glycolysis.After meal, carbohydrates in the food we eat are reduced into simplest form, glucose. Excess glucose removed from body and converted into glycogen in a process called glycogenesis.
Many studies approved that type 2 diabetes and hepatogenous diabetes are associated with increased risk of complication of chronic liver diseases and mortalityGenetic factors play a major role as well. HCV is considered a diabetogenic agent through multiple mechanisms: autoimmune phenomena, direct cytotoxic effect on pancreatic cells, and, blockage of insulin receptors at cellular levels. Alcoholic chronic liver disease affect both hepatocytes and pancreatic islet cells. Diagnosis of hepatogenous diabetes may be difficult as clinical manifestation in early stages of chronic liver disease may be absent and fasting plasma glucose may be normal.So in our study we want to identify best investigation to assess diabetes in chronic liver disease patients. Three prospective studies were collected assessing impact of diabetes among chronic liver disease patients; mainly the outcome, and all of them demonstrate lower 5-year cumulative survival
Aim To provide data to augment the standard of care in diabetic patients with chronic liver disease..
Methods Through a formal permission and access to the (VF-IFH) data and recording system.Data are recorded in a paper-based database system. Collection of data will be via copying the data into an excel sheet. Diabetic status; fasting glucose will be used as a gold standard to divide patients into diabetics (abnormal fasting glucose) and non-diabetics (normal fasting glucose level). Assessment of HbA1C values and patients’ diabetic control, as documented in (VF-IFH) database the sample size for this study is 167 of chronic hepatitis C patients
Results The sample size for this study is 167 of chronic hepatitis C patients. Out of 167 questioned patients, 30.54% are diabetics. 25.5% of diabetic patients have normal HA1C (controlled) & 74.5% have abnormal HA1C (uncontrolled). 78.43% of patient have elevated fasting plasma glucose & about 21.57% have normal values.About 56.86% of hepatitis C patients that have diabetes, have abnormal kidney function (elevated serum creatinine).
Conclusion Chronic liver disease affects glucose metabolism, ranging from mere glucose intolerance to overt diabetes, which is known as hepatogenous diabetes.We find that, about 50, 54% of chronic hepatitis C patients are diabetics with 25, 5% have normal HA1C, 74, 5% have abnormal levels. With no limitations, results precisely answer our question, demonstrate that hepatogenous diabetes is a common problem among chronic liver patients and HA1C is not a standard assessment tool for diabetes.Finally, we wait more researches to explain the pathological basis of the mysterious relation between cirrhosis and HA1C.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Consent was obtained or waived by all participants in this study. Research Ethics Committee, Faculty of Medicine, Suez Canal University issued approval 8729553901. The study was conducted after approval of the Research Ethics Committee, Faculty of Medicine, Suez Canal University. (IRB00008451), Approval number (784518484196)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Contact Information (Chairman of the group): Name: Mohamed Khaled Mohamed Ibrahim, Mobile: +20 010 9355 92 78, E-mail: mohamed.khalid.ibrahim{at}gmail.com
1 Prof. Abdelraouf Eldeeb Professor of internal medicine
2 Hebatalla Mohamed Assistant Lecturer
Data Availability
All data produced in the present study are available upon reasonable request to the authors
LIST OF ABBREVIATIONS
- (VF-IFH)
- Virology unit at Ismailia fever hospital
- (SCUH-Hep)
- Suez Canal university hospital hepatology wards
